KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Assets (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Non-Current Assets for 7 consecutive years, with $88.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 18.47% year-over-year to $88.8 million, compared with a TTM value of $385.5 million through Sep 2025, down 16.99%, and an annual FY2024 reading of $104.0 million, down 15.59% over the prior year.
  • Non-Current Assets was $88.8 million for Q3 2025 at Aurinia Pharmaceuticals, down from $93.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $133.0 million in Q2 2023 and bottomed at -$477.6 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $48.0 million, with a median of $93.6 million recorded in 2025.
  • The sharpest move saw Non-Current Assets soared 349.6% in 2023, then dropped 18.47% in 2025.
  • Year by year, Non-Current Assets stood at $30.0 million in 2021, then decreased by 5.73% to $28.3 million in 2022, then soared by 335.23% to $123.3 million in 2023, then dropped by 15.59% to $104.0 million in 2024, then fell by 14.66% to $88.8 million in 2025.
  • Business Quant data shows Non-Current Assets for AUPH at $88.8 million in Q3 2025, $93.6 million in Q2 2025, and $99.1 million in Q1 2025.